Omeros Submits Narsoplimab MAA to EMA for TA-TMA Treatment
June 27, 2025
Omeros Corporation announced the recent submission of a Marketing Authorization Application to the European Medicines Agency for narsoplimab for the treatment of hematopoietic stem cell